James H. Doroshow
- Oncology top 0.05%
- Cancer Treatment and Pharmacology 64
- PARP inhibition in cancer therapy 52
- Colorectal Cancer Treatments and Studies 48
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics 72
- Molecular Biology top 0.2%
- Cancer therapeutics and mechanisms 60
- DNA Repair Mechanisms 57
- Biophysics top 0.1%
- Toxicology top 0.1%
-
- Lung Cancer Treatments and Mutations 55
-
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms 33
- Co-authors
- Kelvin J.A. DaviesYves PommierR. Steven EsworthyShivaani KummarJiuping JiGershon Y. LockerFong‐Fong ChuCharles E. Myers
- Journals
- Journal of Clinical Oncology (113 papers)Cancer Research (54 papers)Cancer Chemotherapy and Pharmacology (32 papers)
- Partner nations
- United StatesMalaysiaCanada
In The Last Decade
James H. Doroshow
555 papers receiving 25.0k citations
Hit Papers
Peers
Comparison fields: 5 of 191
- Oncology 11.0k
- Cancer Research 3.4k
- Molecular Biology 12.5k
- Biophysics 999
- Toxicology 544
Countries citing papers authored by James H. Doroshow
This map shows the geographic impact of James H. Doroshow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James H. Doroshow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James H. Doroshow more than expected).
Fields of papers citing papers by James H. Doroshow
This network shows the impact of papers produced by James H. Doroshow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James H. Doroshow. The network helps show where James H. Doroshow may publish in the future.
Co-authorship network
The 25 scholars most cited alongside James H. Doroshow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 11 | |
| 3 | 2020 | 30 | |
| 4 | 2018 | 7 | |
| 5 | 2017 | 214 | |
| 6 | 2016 | 24 | |
| 7 | 2015 | 79 | |
| 8 | 2015 | 19 | |
| 9 | 2015 | 255 | |
| 10 | 2014 | 122 | |
| 11 | 2013 | 156 | |
| 12 | 2012 | 155 | |
| 13 | 2012 | 388 | |
| 14 | Trapping of PARP1 and PARP2 by Clinical PARP Inhibitorsbreakdown → | 2012 | 1613 |
| 15 | 2011 | 100 | |
| 16 | 2010 | 60 | |
| 17 | 2010 | 56 | |
| 18 | 2010 | 75 | |
| 19 | 2010 | 239 | |
| 20 | 2009 | 126 |
About James H. Doroshow
James H. Doroshow is a scholar working on Oncology, Cancer Research and Molecular Biology, having authored 582 papers that have together received 25.6k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (72 papers), Cancer Treatment and Pharmacology (64 papers), Cancer therapeutics and mechanisms (60 papers), DNA Repair Mechanisms (57 papers), Lung Cancer Treatments and Mutations (55 papers), PARP inhibition in cancer therapy (52 papers), Colorectal Cancer Treatments and Studies (48 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (33 papers). The work is most often cited by research in Oncology (11.0k citations), Cancer Research (3.4k citations) and Molecular Biology (12.5k citations). James H. Doroshow has collaborated with scholars based in United States, Malaysia and Canada. Frequent co-authors include Kelvin J.A. Davies, Yves Pommier, R. Steven Esworthy, Shivaani Kummar, Jiuping Ji, Gershon Y. Locker, Fong‐Fong Chu, Charles E. Myers, Yiping Zhang and Junko Murai. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.